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In man, when the urine is kept acidic, amphetamines are deaminated to an 
extent of 30% and excreted into the urine unchanged to an extent of 70% of the 
dose. With the assumption that from each amount of amphetamine, as original 
compound or circulating as metabolite, 70% is excreted unchanged and 30% is 
deaminated, the percentages of deamination, dealkylation and excretion of AT-alkyl 
substituted amphetamines can be measured and calculated. In the series of 
iV-methyl, iV-ethyl, and iV-isopropyl amphetamines, the percentage of deamina­
tion remained fairly constant, but the dealkylation increased and excretion 
decreased. The dextro isomers showed this behaviour, but the laevo isomers did 
not. In this series we were dealing with a change in the mode of the C -H  binding 
o f the alkyl group. It was supposed that the C-H  binding was involved in the 
rate-limiting step of the enzymic oxidative deamination and dealkylation. 
Therefore, the amphetamines were deuterated, and under identical circum- 
stances the difïerence in metabolic behaviour of isopropyl- and deuteroisopropyl- 
amphetamine was measured. The dextro isomers showed a deuterium isotope 
effect, the laevo isomers did not (Vree, et al., 1971).
The mixed function oxidase, cytochrome P-450, showed an increased affinity 
for the dextro isomers, as the size of the alkyl group is increased (Schenkman, 
Orrhenius & Hoffstrom, personal communication). Ephedrines show the same 
metabolic pathways as the amphetamines. With the amphetamines the stereo- 
chemical configuration of the tertiary C -H  binding is the key in the deamination 
and dealkylation (Vree, et al., 1971). When the interaction of this C -H  group 
with the enzyme is hindered it affects deamination and dealkylation. The 
hydroxyl group of the ephedrines may also hinder deamination and dealkylation. 
T o show any difference in metabolic behaviour, the extent of metabolism to 
total excretion should be significant, so the 2S (dextro configuration of the 
amphetamines) configuration was chosen. The ephedrines are less lipid-soluble 
than the corresponding amphetamines (Vree, Muskens & van Rossum, 1969). 
The most pronounced difference in metabolic behaviour was expected for the 
IR, 2S and IS, 2S isopropylnorephedrine and the results are given in the table. 
The results found with the IS, 2S ephedrines are in agreement with those 
published by Wilkinson & Beckett (1968).
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D ifferences betw een  re n a l excretion , dealkylation  an d  deam in a tio n  of IR , 2S 
an d  IS, 2S alkylsubstitu ted  n o rephedrines
Compound
(Percentage dose)
Excretion Dealkylation Deamination
IR, 2S norephedrine 75 — 25
methyl-norephedrine 60 15 25
ethyl-norephedrine 40 25 30
isopropyl-norephedrine 20 50 30
IS, 2S norpseudoephedrine 95 — 5
methyl-norpseudoephedrine 85 7 8
ethyl-norpseudoephedrine 60 15 25
isopropyl-norpseudoephedrine 40 20 40
nor-ephedrine (e ) 
erythró-1R,2S
nor-ephedrine(s)
t-hreo-1S,2S
25 - amphetamine (s)
R = H, methyl, ethyl, isopropy I
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